Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sofosbuvir

- PMLiVE

Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment

Use of Veklury among this patient population has previously been limited

- PMLiVE

Gilead’s chronic hepatitis D antiviral shows long-term efficacy in late-stage trial

Hepatitis D virus is estimated to affect more than 230,000 people in the US and Europe

- PMLiVE

COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP

Pfizer’s oral antiviral was granted accelerated approval in the US in December 2021

EU flag

EIT Health and IHI join forces to support health research and innovation across Europe

The organisations have signed a MoU to formalise the collaboration

- PMLiVE

Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations

Veklury demonstrated a reduction in mortality and hospital readmission rates

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

Gilead announces positive new data for Trodelvy in metastatic breast cancer

The treatment demonstrated consistent efficacy across Trop-2 expression levels

- PMLiVE

NHS England set to be first in world to eliminate hepatitis C by 2030

Deaths from the virus fell by 35% following an antiviral drugs deal worth almost £1bn

- PMLiVE

Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations

After changing to Biktarvy, 98% of patients in two groups were suppressed at week 48

- PMLiVE

Gilead’s Vemlidy gets FDA approval for paediatric patients with chronic hepatitis B infection

The application was supported by positive 24-week data from a phase 2 trial

- PMLiVE

Gilead’s latest Biktarvy data offers hope to HIV patients

The data was shared at the 30th International Congress on Drug Therapy in HIV Infection

- PMLiVE

Gilead and MacroGenics enter $1.7bn oncology partnership

The collaboration will focus on developing bispecific antibodies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links